Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis – case report
| Autor: | Oliver Beuing, Michaela Butryn, Jens Neumann, Christian D. Muller, Eugen Feist, Sabine Mewes |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Neurology Hemorrhage Case Report adverse effects [Antibodies Monoclonal Humanized] Antibodies Monoclonal Humanized Gastroenterology 03 medical and health sciences chemistry.chemical_compound diagnostic imaging [Posterior Leukoencephalopathy Syndrome] 0302 clinical medicine Tocilizumab drug therapy [Giant Cell Arteritis] Internal medicine medicine Humans Neurochemistry diagnosis [Posterior Leukoencephalopathy Syndrome] 030212 general & internal medicine ddc:610 skin and connective tissue diseases RC346-429 Aged Giant cell arteritis business.industry Posterior reversible encephalopathy syndrome General Medicine therapeutic use [Antibodies Monoclonal Humanized] medicine.disease diagnostic imaging [Hemorrhage] Magnetic Resonance Imaging Blood pressure chemistry etiology [Posterior Leukoencephalopathy Syndrome] Female Posterior Leukoencephalopathy Syndrome Neurology (clinical) Neurosurgery Epileptic seizure Neurology. Diseases of the nervous system medicine.symptom business 030217 neurology & neurosurgery pathology [Giant Cell Arteritis] |
| Zdroj: | BMC Neurology, Vol 21, Iss 1, Pp 1-3 (2021) BMC neurology 21(1), 228 (2021). doi:10.1186/s12883-021-02231-7 BMC Neurology |
| ISSN: | 1471-2377 |
| DOI: | 10.1186/s12883-021-02231-7 |
| Popis: | Backround We describe one of the first cases of a Posterior reversible encephalopathy syndrome (PRES) under tocilizumab as treatment of Giant cell arteritis (GCA). Case presentation A 65-year-old female with known GCA and treatment with Tocilizumab (TCZ) developed a convulsive epileptic seizure for the first time. MRI was suggestive of PRES and an associated left sided occipital hemorrhage. Extensive high blood pressure values were not detected. The patient recovered within a week and no further seizures occurred under anticonvulsive medication. Conclusion PRES during the treatment with Tocilizumab hasn’t been described in GCA so far. There are single reports of an association between TCZ and PRES in other entities. Thus, a link between interleukin-6 and the integrity of the vasculature could be considered. The clinical consequence should be a stringent blood pressure monitoring in the ambulant setting of patients receiving TCZ. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|